Positive survival data from KEYNOTE-905 and KEYNOTE-B96 to be featured in Presidential Symposium, underscoring the impact of KEYTRUDA ® (pembrolizumab) in certain bladder and ovarian cancers Data from ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈